Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study

Abstract

This cohort retrospective study explored the cost and clinical consequences of smoking cessation in outpatients after cardiovascular events (CVEs), in Spain. A total of 2,540 patients (68.1 years; 60.7% male; 8.4% smokers, 52.9% ex-smokers, and 38.7% never smokers) fulfilling the selection criteria and followed up throughout a period of 36 months after the event were considered eligible for analysis. Total costs were higher among current smokers in comparison with ex-smokers and never smokers (€7,981 versus [vs] €7,322 and €5,619, respectively) (P < 0.001). Both health care costs (€6,273 vs €5,673 and €4,823, respectively) (P < 001) and loss of productivity at work costs (€1,708 vs €1,650 and €796, respectively) (P < 001) accounted for such differences. There was also a difference in CVE recurrence rates (18.6% vs 16.5% and 9.6%, respectively) (P < 01). Smoking cessation in CVE outpatients was associated with lower cost and risk of CVE recurrence compared with smokers, and their health status was similar to that of never smokers, in routine clinical practice in Spain.

Keywords:

• mortality
• health resources
• health care costs

Acknowledgments

The authors wish to thank Javier Rejas for reviewing the manuscript and for his valuable comments and suggestions regarding the final version of the manuscript.

Disclosure

This study was sponsored by Pfizer SLU. Verónica Sanz de Burgoa is an employee of Pfizer SLU. Silvia Diaz-Cerezo was a former employee of Pfizer SLU at the time of completion of the study and manuscript preparation. She is no longer working for Pfizer SLU. Antoni Sicras-Mainar was a paid consultant to Pfizer in connection with the development of this manuscript. The statistical analysis was performed by DataClinics and was funded by Pfizer SLU. The authors report no other conflicts of interest in this work.